-
Global Trends
Strategic Collaboration to Expand Cardiometabolic Pipeline
On December 9, 2025, a major pharmaceutical corporation based in New York announced it had entered into an exclusive global…
Read More » -
M&A
Mirum Pharmaceuticals Expands Portfolio With Bluejay Therapeutics Acquisition
Transaction Overview and Terms Mirum Pharmaceuticals Inc., a specialty pharmaceutical company focused on rare diseases, has reached an agreement to…
Read More » -
M&A
Viatris Exits Preferred Equity Stake in Biocon Biologics in Major Transaction
The global healthcare enterprise Viatris has executed definitive agreements for the divestiture of its entire convertible preferred equity holding in…
Read More » -
M&A
Sandoz Finalizes Acquisition of Just-Evotec Biologics EU SAS, Reinforcing Biosimilars Leadership
(Basel, December 8, 2025) – Sandoz Group AG (SIX: SDZ/OTCQX: SDZNY), the global leader in affordable medicines, announced the successful…
Read More » -
Global Trends
AstraZeneca’s Dual-Targeting CAR-T Shows Encouraging Efficacy
(ASH Congress) – AstraZeneca (AZ) announced positive clinical data for its leading cell therapy candidate, AZD0120 (formerly GC012F), for the…
Read More » -
Global Trends
Crescent and Kelun-Biotech Execute Double Deal to Swap Cancer Asset Rights
The pharmaceutical companies Crescent Biopharma (US-based) and Kelun-Biotech (China-based) have announced a strategic partnership to exchange licensing rights for two…
Read More » -
Global Trends
Trial Data Opens Door for Earlier Use of Lilly’s BTK Inhibitor
(ORLANDO) – At an American Society of Hematology (ASH) meeting, the pharmaceutical company Eli Lillypresented results from a critical head-to-head…
Read More » -
Corporate Wellness
Stroke Recovery: When Every Movement Becomes Hope
The journey of recovery after a stroke is a major challenge faced by many families in Vietnam. It is not…
Read More » -
M&A
Pharma Megamerger: Major Drug Company Unifies $5.5 Billion Biologics Subsidiary
A major pharmaceutical company has announced the successful completion of a plan to fully integrate its Biologics subsidiary, officially making…
Read More » -
Global Trends
AstraZeneca Expands Amyloidosis Collaboration with Deal Potentially Reaching $780 Million
Alexion Pharmaceuticals, the rare disease unit of AstraZeneca, has expanded its partnership with biotech company Neurimmune by licensing a second…
Read More » -
Global Trends
Major Funding Deal: Therapeutics Company Secures $275 Million Through Drug Royalty Agreement
A therapeutics company has announced a funding agreement worth $275 million with a financial fund specializing in pharmaceutical royalties. The…
Read More » -
M&A
Minimum Acceptance Threshold Met in Exchange Proposal Between Two Biotech Firms
(MAINZ, Germany, December 3, 2025) – The biotech firm BioNTech (Nasdaq: BNTX) recently announced that the minimum condition for its…
Read More » -
Global Trends
A New Breakthrough in Duchenne Muscular Dystrophy Treatment: Promising Phase 3 Trial Results
A therapeutics company has announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial, evaluating the efficacy of…
Read More » -
Local Dynamics
Strategic Alliance: French Pharmaceutical Group Partners with Major Drugstore Chain
A reputable pharmaceutical corporation from France, with over seven decades of experience in the research, production, and distribution of healthcare…
Read More » -
Local Dynamics
Pharmaceutical Update: Regulatory Body Approves and Renews Nearly 600 Drug Licenses
The Pharmaceutical Management Agency under the Ministry of Health of Vietnam has announced a new list of approximately 600 drug…
Read More » -
Local Dynamics
Expanding Horizons: The Growth Journey of a Private Healthcare Group
The establishment of a specialized obstetrics and gynecology facility in Can Tho led to the formation of a healthcare group…
Read More » -
Global Trends
European Authorities Clear Novel Autoimmune Therapy for Myasthenia Gravis
The European Commission has granted authorization for nipocalimab, an immunoglobulin G (IgG) receptor antagonist developed by Johnson & Johnson, for…
Read More » -
M&A
Eli Lilly Secures Experimental Cancer Therapy from Scorpion in Up-to-$2.5 Billion Deal
Eli Lilly announced its plan to acquire an experimental cancer therapy from Scorpion Therapeutics for a total consideration of up…
Read More » -
M&A
???? Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion to Boost Cardiovascular Pipeline
The Swiss pharmaceutical giant Novartis has reached an agreement to acquire Anthos Therapeutics, a biopharmaceutical firm majority-owned by the life…
Read More » -
M&A
Merck Finalizes $3.4 Billion Acquisition, Enhancing Rare Tumor Portfolio
Merck has successfully completed its previously announced $3.4 billion acquisition of SpringWorks Therapeutics, a biopharmaceutical company based in Stamford, Connecticut.…
Read More »
